Rob Stein
Rob Stein is a correspondent and senior editor on NPR's science desk.
An award-winning science journalist with more than 30 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues, and other science, medical, and health policy news.
Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.
Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science, the American Association for Cancer Research, and the Association of Health Care Journalists. He was twice part of NPR teams that won Peabody Awards.
Stein frequently represents NPR, speaking at universities, international meetings and other venues, including the University of Cambridge in Britain, the World Conference of Science Journalists in South Korea, and the Aspen Institute in Washington, DC.
Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.
-
But the researchers stressed that all three vaccines, including the Pfizer and Johnson & Johnson shots, provide strong protection against people getting so sick that they end up in the hospital. -
As the delta surge continues, there are signs it may be slowing in hard-hit states like Florida and Texas. But with fall coming, experts worry another surge could hit northern states.
-
As the delta variant causes more vaccinated people to get "breakthrough infections," concerns are rising that even the vaccinated could develop long COVID symptoms in rare cases. -
The Biden administration plans to unveil another strategy to fight the latest COVID-19 surge driven by the delta variant, after a series of setbacks and missteps in the battle against the pandemic.
-
The company said that when study participants were given a second jab after six months, their antibody levels were nine times higher than they were 28 days after a first dose of the COVID-19 vaccine.
-
Johnson & Johnson said that when it gave study participants a second jab after six months, their antibody levels were nine times higher than they were 28 days after a first dose of the COVID vaccine. -
FDA gives full approval to Pfizer's COVID-19 vaccine, a highly anticipated move that could give the nation's vaccination campaign a badly needed boost.
-
The latest coronavirus surge is ratcheting up fears about the toll, and intensifying pressure to get more people vaccinated, wearing masks and perhaps start offering booster shots.
-
The CDC information dated Thursday gives new details on this variant of the coronavirus and says the agency should "acknowledge that the war has changed." It was first reported by The Washington Post. -
A small Israeli study of vaccinated health care workers found that a handful who got infected developed headaches, muscle pain, fatigue and other symptoms of long COVID that lasted for weeks.
